BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 19861464)

  • 1. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
    Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
    Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody.
    Terabe M; Ambrosino E; Takaku S; O'Konek JJ; Venzon D; Lonning S; McPherson JM; Berzofsky JA
    Clin Cancer Res; 2009 Nov; 15(21):6560-9. PubMed ID: 19861451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
    Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
    J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor localization of an anti-TGF-β antibody and its effects on gliomas.
    Hülper P; Schulz-Schaeffer W; Dullin C; Hoffmann P; Harper J; Kurtzberg L; Lonning S; Kugler W; Lakomek M; Erdlenbruch B
    Int J Oncol; 2011 Jan; 38(1):51-9. PubMed ID: 21109925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective Treatment of Established GL261 Murine Gliomas through Picornavirus Vaccination-Enhanced Tumor Antigen-Specific CD8+ T Cell Responses.
    Renner DN; Jin F; Litterman AJ; Balgeman AJ; Hanson LM; Gamez JD; Chae M; Carlson BL; Sarkaria JN; Parney IF; Ohlfest JR; Pirko I; Pavelko KD; Johnson AJ
    PLoS One; 2015; 10(5):e0125565. PubMed ID: 25933216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners.
    Zhu X; Fallert-Junecko BA; Fujita M; Ueda R; Kohanbash G; Kastenhuber ER; McDonald HA; Liu Y; Kalinski P; Reinhart TA; Salazar AM; Okada H
    Cancer Immunol Immunother; 2010 Sep; 59(9):1401-9. PubMed ID: 20549206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
    Zhu X; Nishimura F; Sasaki K; Fujita M; Dusak JE; Eguchi J; Fellows-Mayle W; Storkus WJ; Walker PR; Salazar AM; Okada H
    J Transl Med; 2007 Feb; 5():10. PubMed ID: 17295916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.
    Liu VC; Wong LY; Jang T; Shah AH; Park I; Yang X; Zhang Q; Lonning S; Teicher BA; Lee C
    J Immunol; 2007 Mar; 178(5):2883-92. PubMed ID: 17312132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
    Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells.
    Jarnicki AG; Lysaght J; Todryk S; Mills KH
    J Immunol; 2006 Jul; 177(2):896-904. PubMed ID: 16818744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.
    Fujita M; Zhu X; Ueda R; Sasaki K; Kohanbash G; Kastenhuber ER; McDonald HA; Gibson GA; Watkins SC; Muthuswamy R; Kalinski P; Okada H
    Cancer Res; 2009 Feb; 69(4):1587-95. PubMed ID: 19190335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel recombinant protein of IP10-EGFRvIIIscFv and CD8(+) cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice.
    Wang X; Lu XL; Zhao HY; Zhang FC; Jiang XB
    Cancer Immunol Immunother; 2013 Jul; 62(7):1261-72. PubMed ID: 23640602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
    Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
    Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma.
    Ueda R; Low KL; Zhu X; Fujita M; Sasaki K; Whiteside TL; Butterfield LH; Okada H
    J Transl Med; 2007 Dec; 5():68. PubMed ID: 18093336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model.
    Prins RM; Odesa SK; Liau LM
    Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a glioma antigen, GARC-1, using cytotoxic T lymphocytes induced by HSV cancer vaccine.
    Iizuka Y; Kojima H; Kobata T; Kawase T; Kawakami Y; Toda M
    Int J Cancer; 2006 Feb; 118(4):942-9. PubMed ID: 16152596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site-specific anti-tumor immunity: differences in DC function, TGF-beta production and numbers of intratumoral Foxp3+ Treg.
    Biollaz G; Bernasconi L; Cretton C; Püntener U; Frei K; Fontana A; Suter T
    Eur J Immunol; 2009 May; 39(5):1323-33. PubMed ID: 19337997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors.
    Agarwalla P; Barnard Z; Fecci P; Dranoff G; Curry WT
    J Immunother; 2012 Jun; 35(5):385-9. PubMed ID: 22576343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
    Davila E; Kennedy R; Celis E
    Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.